Physician

Adam Brandon Blechman, MD

According to 2025 Medicare claims, Adam Blechman, MD (NPI: 1578908018) practices micrographic dermatologic surgery in the Montgomery County-Bucks County-Chester County, PA market, with the plurality of this provider's patient population coming from Bucks, PA. This provider's primary affiliated billing organization is PENNSYLVANIA DERMATOLOGY PARTNERS INC (NPI: 1023382918; TIN: 454600640) and primary practice location at 19067-7700.

Blechman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 714 traditional Medicare patients, billed 5,039 HCPCS/CPT codes, and received $609,061 in Medicare payments. The top billing code was 17110 (Destruction of skin growth, 1-14 growths). Part D data shows 830 prescription claims across 432 beneficiaries totaling $300,462 in drug costs, led by Clobetasol Propionate (Clobetasol Propionate). Open Payments data shows 115 records totaling $2,292. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $70,554 to $609,061. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $39,051 and ending at $300,462. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$305K$609K2018 Medicare payment: $70,554 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $290,188 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $217,125 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $314,569 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $387,895 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $480,997 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $609,061 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
2018174577$70,554
20192861,599$290,188
20203191,344$217,125
20213211,543$314,569
20223902,016$387,895
20236994,183$480,997
20247145,039$609,061

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$150K$300K2015 Drug cost: $39,051 (USD; Tot_Drug_Cst)2016 Drug cost: $36,983 (USD; Tot_Drug_Cst)2017 Drug cost: $124,490 (USD; Tot_Drug_Cst)2018 Drug cost: $11,313 (USD; Tot_Drug_Cst)2019 Drug cost: $26,801 (USD; Tot_Drug_Cst)2020 Drug cost: $13,131 (USD; Tot_Drug_Cst)2021 Drug cost: $10,764 (USD; Tot_Drug_Cst)2022 Drug cost: $3,422 (USD; Tot_Drug_Cst)2023 Drug cost: $39,481 (USD; Tot_Drug_Cst)2024 Drug cost: $300,462 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015130273$39,051
2016108198$36,983
201795181$124,490
2018131258$11,313
2019217460$26,801
2020157295$13,131
2021168284$10,764
2022162267$3,422
2023361669$39,481
2024432830$300,462

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
17110Destruction of skin growth, 1-14 growths200247$84
11102Biopsy of related skin growth, first growth261325$66
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more446724$65
17000Destruction of precancer skin growth, 1 growth331448$35
17003Destruction of precancer skin growth, 2-14 growths2321,285$5

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Clobetasol PropionateClobetasol Propionate952,849$5,020
MetronidazoleMetronidazole12652$1,413
CephalexinCephalexin106742$1,398
KetoconazoleKetoconazole742,104$1,184
Triamcinolone AcetonideTriamcinolone Acetonide882,835$851

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.115$2,292Janssen Biotech, Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Adam Brandon Blechman, MD?

Tedicare shows public-source Medicare data for Adam Brandon Blechman, MD (NPI 1578908018), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adam Brandon Blechman, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Adam Brandon Blechman, MD?

Adam Brandon Blechman, MD is linked to PENNSYLVANIA DERMATOLOGY PARTNERS INC (billing NPI 1023382918) in the available physician profile data.

Does Adam Brandon Blechman, MD have Open Payments data?

Adam Brandon Blechman, MD has 115 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.